Strides Pharma Science

Strides Pharma Science Limited has entered into a strategic partnership with Kenox Pharmaceuticals to jointly develop and commercialize a range of nasal sprays, marking a significant step in the specialty pharmaceutical segment. This collaboration aims to leverage Strides’ global distribution capabilities and Kenox’s research expertise in inhalation therapies. With growing demand for user-friendly drug delivery systems, particularly in respiratory and neurological care, the partnership is expected to strengthen both companies’ positions in regulated markets.

The Reserve Bank of India (RBI) is set to declare its dividend payout to the central government for the fiscal year 2024-25, with expectations of an amount exceeding the record Rs 2.1 lakh crore transferred in 2023-24. This anticipated increase follows a recent review of the RBI’s Economic Capital Framework (ECF), a critical determinant of surplus transfers. The upcoming decision, scheduled for the Central Board of Directors meeting on May 23, reflects prudent risk management strategies and fiscal discipline amid heightened economic uncertainties.

Strides Pharma Science delivered a remarkable financial performance in the March quarter, posting a net profit of Rs 85.61 crore—an impressive surge from Rs 10.44 crore in the same quarter last year. Revenue climbed 16.7% year-over-year to Rs 1,202.37 crore, driven primarily by strong traction in the US market. Despite an increase in expenses, the company outperformed its revenue guidance of 12-15%, closing FY25 with a 17.2% growth.